NCT06909825
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06909825
Title FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Fusion Pharmaceuticals Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS

Facility Status City State Zip Country Details
Macquarie University Hospital Macquarie Park New South Wales 2113 Australia Details
Princess Alexandra Hospital Woolloongabba Queensland 4102 Australia Details
Icon Cancer Centre Kurralta Park Kurralta Park South Australia 5037 Australia Details
Peter MacCallum Cancer Center Melbourne Victoria 3000 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field